
The BRIGHT Study: Comparing Toujeo® (insulin glargine 300 U/mL) and Insulin Degludec 100 U/mL
Efficacy and safety considerations are essential for effective Type 2 diabetes management.
This website contains promotional content and is intended for Healthcare Professionals based in the United Kingdom only. Some content may only be relevant to HCPs practising in Great Britain (England, Scotland and Wales) according to product availability. This website is optimised for desktop use, and some features may perform differently on mobile devices.
Adverse event reporting can be found at the bottom of the page.


Efficacy and safety considerations are essential for effective Type 2 diabetes management.

A short video raising awareness of Pompe disease

A short video outlining the mechanism of Pompe disease

Praluent® (alirocumab) Administration
.jpg)

Read to learn more about what tools can help you identify your patients with uncontrolled AD
Beyfortus®▼ (Nirsevimab)

Read to learn more about the burdens of uncontrolled AD.

Read to learn more about the concept of CLCI, how it manifests in atopic dermatitis and its impact on patients.
MAT-XU-2305061 (v2.0) Date of preparation: February 2024